During cancer progression, this immune inhibitory pathway is activated when PD-1 ligands (PD-L1 and PD-L2) are upregulated on either tumor or immune cells in the tumor microenvironment (TME) and permits evasion from antitumor immune surveillance (11). Here, PDCD1LG2 is linked to neoplasm.